Summary
TASER International, Inc. (now Axon Enterprise, Inc.) reported net sales of $92.8 million for the fiscal year ended December 31, 2008, a decrease of 8% from $100.7 million in 2007. This decline was primarily attributed to reduced municipal spending in the U.S. due to the economic downturn, impacting sales of its core TASER X26 product and cartridges. However, the company saw growth in international sales, which represented 18% of total sales in 2008, up from 15% in 2007, with notable advances in the United Kingdom. The company significantly increased its investment in research and development, spending $12.9 million in 2008 compared to $4.4 million in 2007, focusing on new product introductions such as the TASER AXON and EVIDENCE.com platform, expected in 2009. Despite the revenue decrease, gross margins improved to 61.4% in 2008 from 57.1% in 2007 due to cost control and manufacturing efficiencies. The company ended the year with a strong balance sheet, reporting $49.4 million in cash and investments with no debt, providing flexibility for future investments.
Key Highlights
- 1Net sales decreased by 8% to $92.8 million in 2008, primarily due to a decline in U.S. law enforcement spending amid economic challenges.
- 2International sales increased their share of total revenue to 18% in 2008, indicating successful market expansion outside the U.S.
- 3Significant investment in R&D ($12.9 million in 2008) to support new product development, including TASER AXON and EVIDENCE.com, with planned 2009 launches.
- 4Gross margin improved to 61.4% in 2008 from 57.1% in 2007, driven by cost efficiencies and manufacturing improvements.
- 5The company maintained a strong financial position with $49.4 million in cash and investments and no outstanding debt as of December 31, 2008.
- 6Despite revenue decline, the company successfully defended against product liability lawsuits, with 18 dismissals in 2008.
- 7The TASER C2 consumer product showed growth, contributing $6.1 million in revenue in 2008.